Biop Medical
announced the launch of its high tech, point of care cervical cancer screening and
detection device at MEDICA 2017 in Düsseldorf, Germany, Nov. 13-16. This "sample
free biopsy" device helps gynecologist in screening and diagnosis of pre-cancerous
and cancerous lesions in real time without the painful wait for the biopsy results.
Biop system
is a digital colposcope that make use of advanced and high-resolution optics to
obtain a magnified view of vagina, cervix and external genitalia, allowing
doctors to identify abnormalities such as lesions or cancer and selecting
areas for biopsy.
The
innovative system consists of a main control unit, that can be connected to the
Digital Colposcope unit or the Micro-Colposcope Probe unit.
A fully
digital and high-resolution imaging of the cervix can be performed by
connecting the Digital Colposcope unit to the control unit. Panoramic color
images, using LED lights are acquired by the camera.
On the other
hand, the Micro- Colposcope Probe unit captures a macro-image of the cervix,
using its macro-camera. Using a sterile and disposable cover, the probe is
advanced in the vagina, upon coming in contact with the cervix, the unit
captures high-resolution, high-magnification images within a radius of
11mm around the external os, which serves as the center of the scan.
The
physician does not need to constantly adjust the magnification, to focus on the
specific areas, as with the current colposcopy units.
The images
are enhanced and processed by the software of the system. The high resolution, macro
images are than combined with the panoramic images to obtain a full a color map
of cervix, that is analyzed by Biop’s proprietary algorithm.
Two pictures
are displayed on the physician's screen; a high-resolution photograph of the
patient's cervix, immediately next to a hot/cold map indicating a precise
classification and location of any diseased lesions.
If needed,
the physician can take biopsies from a precise location, and reducing the need
for unnecessary biopsies.
The data
obtained is uploaded and secured on Bluemix virtual servers in the IBM
Cloud and can be used for consultation with any specialist around the world. These
new data sets can be used to improve the accuracy of Biop’s diagnostic and
create predictive data, which will determine which cells are likely to convert
to cancer and which will regress to healthy cells.
With Biop, a
woman can be screened in 3 minutes and if precancerous or cancerous lesions are
detected, the women can be referred for immediate treatment.
The device
is particularly useful in developing countries, and remote access areas where
the physician can carry the device to the patients.
Operating the
device requires minimum screening, so that healthcare professional can be
quickly trained to do the scanning, as compared to years of training required
for routine colposcopy.
“With this
new precision, physicians can see where to target biopsies and only perform the
procedure when necessary,” said Biop Medical CEO Ilan Landesman in a news release. “Patients gain a more accurate and faster diagnosis while avoiding the
painful procedure as well as reduced costs for hospitals and healthcare
providers.”
Cervical
cancer is the number one cause of cancer-related death for women in the
developed world. Out of BRICS (Brazil, Russia, India and China
and South Africa) countries, India is the leader in overall deaths,
with nearly 73,000 annual deaths. China and Brazil follow closely.
Biop Medical is
based in Ramat Gan, Israel.
Media courtesy: Biop
No comments:
Post a Comment